Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Megapharm Ltd.

Division of MegaPharm Ltd.
www.megapharm.co.il

Latest From Megapharm Ltd.

Pipeline Watch: Phase III Starts With Fasinumab, Varlitinib

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

FDA yes for Salix's previously delayed Ruconest

Salix Pharmaceuticals has received a green light from the US FDA to market Ruconest (recombinant C1 esterase inhibitor) for the treatment of acute angioedema attacks in adult and adolescent patients with hereditary angioedema (HAE).

Gastrointestinal Cardiovascular

Pharming/Santarus’ Recombinant HAE Drug Ruconest Goes Back To FDA

A BLA has been re-submitted to FDA for Ruconest, which is differentiated from other C1 esterase inhibitors by its recombinant structure. But as the fifth drug for the rare hereditary angioedema condition in the U.S. market, commercial expectations are low.

BioPharmaceutical Clinical Trials

Pharming/Santarus’ Recombinant HAE Drug Ruconest Goes Back To FDA

A BLA has been re-submitted to FDA for Ruconest, which is differentiated from other C1 esterase inhibitors by its recombinant structure. But as the fifth drug for the rare hereditary angioedema condition in the U.S. market, commercial expectations are low.

BioPharmaceutical United States
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Pharmaceuticals
    • OTC, Consumer
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Middle East
      • Israel
  • Parent & Subsidiaries
  • MegaPharm Ltd.
  • Senior Management
  • Miron Drucker, CEO
    Carni Gaoni, VP, COO
    Issy Peimer, Mgr., Bus. Dev.
    Hila Len, Mgr., Mktg.
  • Contact Info
  • Megapharm Ltd.
    Phone: (972) 9 7604596
    Hapnina Street 8, Building B
    1st Floor
    Raanana, 43215
    Israel
Advertisement
Advertisement
UsernamePublicRestriction

Register